Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial
BJU International · 2023
DOI: 10.1111/bju.16033 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2023. Verfasst von Andrew Zganjar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Erectile Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To report open‐label phase data from a recent randomized controlled trial (RCT), after previous data from that study showed improved penile length and erectile function among post‐prostatectomy men treated with Restorex penile traction therapy (RxPTT). Materials and Methods An RCT (NCT05244486) was performed to evaluate RxPTT vs no treatment (Tx) for 5 months, which was followed by a 3‐month open‐label phase. Men were stratified based on as‐treated data: Group 1 = No Tx; Group 2 = No Tx → Tx; Group 3 = Tx → No Tx; Group 4 = Tx. Assessments included stretched penile length and standardized (International Index of Erectile Function [IIEF]) and non‐standardized questionnaires.
Results
A total of 82 men were enrolled (mean age 58.6 years) with 9‐month data available in 45 of the men. Baseline characteristics were similar among the cohorts. Comparing Group 1 and Group 4 (respectively), notable differences included: IIEF Erectile Function domain (IIEF‐EF) score (−8 vs −0.5; P = 0.16), penile length (−0.1 vs +1.7 cm; P < 0.01), intracavernosal injection use (86% vs 14%; P < 0.01), Sexual Encounter Profile (SEP) Question 2 (50% vs 100%; P < 0.01), SEP Question 3 (33% vs 100%; P < 0.01). Men who crossed over to Tx (Group 2) failed to achieve equivalent improvements in length (+0.5 cm) or sexual function (IIEF‐EF score −6) compared to men treated early (Groups 3 and 4). Those who crossed over to no treatment after initial treatment (Group 3) experienced preserved length (+1.8 cm), and erectile function (IIEF‐EF score +0) despite therapy discontinuation.
Conclusions
Use of RxPTT beginning 1 month post‐prostatectomy results in improved penile length and erectile function, with benefits maintained after discontinuing therapy. If confirmed, these results represent the first postoperative therapy shown in a RCT to improve erectile function post‐prostatectomy. External validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic, Rochester, MN, USA.
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Male Fertility and Peyronie's Clinic, Orem, UT, USA.
ORCID-Profile: Matthew Ziegelmann, Landon Trost
Zitieren
APA
Zganjar, A., Toussi, A., Ziegelmann, M., Frank, I., Boorjian, S. A., Tollefson, M., Köhler, T., & Trost, L. (2023). Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial. BJU International. https://doi.org/10.1111/bju.16033
Vancouver
Zganjar A, Toussi A, Ziegelmann M, Frank I, Boorjian SA, Tollefson M, et al. Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial. BJU International. 2023. doi:10.1111/bju.16033
BibTeX
@article{Zganjar2023,
author = {Zganjar, Andrew and Toussi, Amir and Ziegelmann, Matthew and Frank, Igor and Boorjian, Stephen A and Tollefson, Matthew and Köhler, Tobias and Trost, Landon},
title = {Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial},
journal = {BJU International},
year = {2023},
doi = {10.1111/bju.16033}
}
EUVIMED